Mark Aguillard
Corporate Officer/Principal bei DERMTECH, INC.
Vermögen: 63 180 $ am 31.03.2024
Profil
Mark Aguillard is currently the Chief Commercial Officer at DermTech, Inc. He was previously the Chief Commercial Officer at Epic Sciences, Inc. from 2021 to 2023.
Aguillard received an undergraduate degree from Texas Tech University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DERMTECH, INC.
0,26% | 20.09.2023 | 90 000 ( 0,26% ) | 63 180 $ | 31.03.2024 |
Aktive Positionen von Mark Aguillard
| Unternehmen | Position | Beginn |
|---|---|---|
| DERMTECH, INC. | Corporate Officer/Principal | 19.09.2023 |
Ehemalige bekannte Positionen von Mark Aguillard
| Unternehmen | Position | Ende |
|---|---|---|
Epic Sciences, Inc.
 Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.09.2023 |
Ausbildung von Mark Aguillard
| Texas Tech University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DERMTECH, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Epic Sciences, Inc.
Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Health Technology |
